Lv1
50 积分 2022-03-30 加入
eNRGy: Making progress toward a future for NRG1 fusion-positive cancer
1天前
求助中
Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study
6天前
已完结
Artificial Intelligence in Accelerating Drug Discovery and Development
7天前
已完结
EGFR-mutated NSCLC: A roadmap to treatment sequences
1个月前
已完结
Antibody-Drug Conjugates in Lung Cancer: Recent Advances and Implementing Strategies
1个月前
已完结
LBA71 First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (uMPM): 4-year update from CheckMate 743
3个月前
已完结
Why We Do Not Recommend That Women With Breast Cancer Receive Adjuvant Treatment With a CDK4/6 Inhibitor
3个月前
已关闭
Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial
3个月前
已关闭
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
3个月前
已完结
皖公网安备34019202002308
